Why the study?
Combining medications is an appealing approach for pulmonary arterial hypertension, but the short-term outcomes of monotherapy versus combination therapy needed comparison.
Does combination therapy (bosentan with oral sildenafil) improve short-term outcomes compared to monotherapy in patients with pulmonary hypertension associated with congenital heart disease?
RCT (n=70)
Random selection
Yes
Does combination therapy (bosentan with oral sildenafil) improve short-term outcomes compared to monotherapy in patients with pulmonary hypertension associated with congenital heart disease?
Combination therapy with bosentan and sildenafil significantly improves short-term functional and hemodynamic parameters compared to monotherapy in patients with PAH associated with congenital heart disease.
Answers are grounded in this paper and cite their sources.
Supports combination bosentan-sildenafil over monotherapy in CHD-PAH; extends mixed prior evidence with RCT confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Anam et al. (2022) conducted an RCT in Pulmonary hypertension associated with congenital heart disease (n=70). Sildenafil and bosentan combination therapy vs. Sildenafil monotherapy was evaluated on 6-minute walking distance (6MWD) at 6 months (p=0.002).
Synapse has enriched 10 related papers. Consider them for comparative context: